文献速递乳腺技术与安全MR

影像组学的方法学问题:对MRI预测乳腺癌新辅助化疗反应准确性的影响

Methodological issues in radiomics: impact on accuracy of MRI for predicting response to neoadjuvant chemotherapy in breast cancer.
PubMed 文献 · Eur Radiol · 2024-12-19

该系统综述纳入截至2023年3月的42项研究,用随机效应Meta分析合并MRI影像组学模型预测乳腺癌新辅助治疗反应的AUC,汇总AUC为0.77(95%CI 0.74-0.81),异质性I²=81%,无发表偏倚(p=0.35)。扫描仪厂商不同(混合厂商AUC 0.70 vs 同一厂商0.74-0.83,与厂商1比较p=0.03)和特征类型(3D AUC 0.81 vs 2D/2.5D AUC 0.73,p=0.03)影响模型准确性。作者结论认为MRI影像组学有潜力但方法学差异大,需优先建立标准化流程并提高方法学严谨性。

要点

  • MRI影像组学预测乳腺癌新辅助治疗反应的汇总AUC为0.77(95%CI 0.74-0.81),异质性I²=81%。
  • 使用混合扫描仪厂商的研究AUC为0.70(95%CI 0.61-0.78),低于同一厂商研究的0.74-0.83。
  • 使用3D图像的研究AUC为0.81(95%CI 0.78-0.85),高于2D/2.5D图像的0.73(95%CI 0.65-0.81),p=0.03。

核心结论

  • MRI影像组学已成为预测乳腺癌患者新辅助治疗反应的潜在方法,结果令人期待,但必须认识到所采用方法学选择的多样性;进一步研究应优先实现标准化流程并提高MRI影像组学的方法学严谨性。

研究设计与样本

  • 系统综述,检索截至2023年3月,纳入42项研究;采用随机效应Meta分析合并受试者工作特征曲线下面积(AUC)值,用Egger检验评估发表偏倚,用I²估计异质性,并进行Meta回归探究扫描仪、特征数量/变换/类型、像素/体素缩放等因素的影响。

诊断标准与关键数值

  • MRI影像组学模型预测乳腺癌新辅助治疗反应的汇总AUC为0.77(95%CI 0.74-0.81)。
  • 使用混合扫描仪厂商的研究AUC为0.70(95%CI 0.61-0.78)。
  • 使用同一扫描仪的研究中,厂商1、厂商2、厂商3的AUC(95%CI)分别为0.83(0.77-0.88)、0.74(0.67-0.82)、0.83(0.78-0.89),与厂商1比较p=0.03。
  • 使用3D图像的研究AUC为0.81(95%CI 0.78-0.85),使用2D/2.5D图像的研究AUC为0.73(95%CI 0.65-0.81),p=0.03。
  • 纳入3D图像的研究异质性I²=33%,纳入厂商1扫描仪的研究异质性I²=40%,均为非显著研究间异质性。

临床应用与阅片要点

  • 作者结论认为MRI影像组学是预测乳腺癌新辅助治疗反应的潜在方法,但方法学选择存在多样性,进一步研究应优先实现标准化流程并提高方法学严谨性。

局限性

  • 观察到显著异质性(I²=81%)。
  • 影像组学模型准确性受扫描仪厂商影响,使用混合扫描仪厂商的研究AUC较低。
  • 特征类型似乎对AUC有影响,3D与2D/2.5D图像之间预测准确性存在差异。
  • 作者指出必须认识到所采用方法学选择的多样性,进一步研究应优先实现标准化流程并提高方法学严谨性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To investigate whether methodological aspects may influence the performance of MRI-radiomic models to predict response to neoadjuvant treatment (NAT) in breast cancer (BC) patients.

MATERIALS AND METHODS: We conducted a systematic review until March 2023. A random-effects meta-analysis was performed to combine the area under the receiver operating characteristic curve (AUC) values. Publication bias was assessed using Egger's test and heterogeneity was estimated by I2. A meta-regression was conducted to investigate the impact of various factors, including scanner, features' number/transformation/type, pixel/voxel scaling, etc. RESULTS: Forty-two studies were included. The summary AUC was 0.77 (95% CI: 0.74-0.81). Substantial heterogeneity was observed (I2 = 81%) with no publication bias (p = 0.35). Radiomic model accuracy was influenced by the scanner vendor, with lower AUCs in studies using mixed scanner vendors (AUC; 95% CI: 0.70; 0.61-0.78) compared to studies including images obtained from the same scanner (AUC (95% CI): 0.83 (0.77-0.88), 0.74 (0.67-0.82), 0.83 (0.78-0.89) for three different vendors; vendors 1, 2, and 3, respectively; p-value = 0.03 for comparison with vendor 1). Feature type also seemed to have an impact on the AUC, with higher prediction accuracy observed for studies using 3D than 2D/2.5D images (AUC; 95% CI: 0.81; 0.78-0.85 and 0.73; 0.65-0.81, respectively, p-value = 0.03). Non-significant between-study heterogeneity was observed in the studies including 3D images (I2 = 33%) and Vendor 1 scanners (I2 = 40%).

CONCLUSION: MRI-radiomics has emerged as a potential method for predicting the response to NAT in BC patients, showing promising outcomes. Nevertheless, it is important to acknowledge the diversity among the methodological choices applied. Further investigations should prioritize achieving standardized protocols, and enhancing methodological rigor in MRI-radiomics.

KEY POINTS: Question Do methodological aspects influence the performance of MRI-radiomic models in predicting response to NAT in BC patients? Findings Radiomic model accuracy was influenced by the scanner vendor and feature type. Clinical relevance Methodological discrepancies affect the performance of MRI-radiomic models. Developing standardized protocols and enhancing methodological rigor in these studies should be prioritized.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Netti S, D'Ecclesiis O, Corso F, et al. Methodological issues in radiomics: impact on accuracy of MRI for predicting response to neoadjuvant chemotherapy in breast cancer. Eur Radiol. 2024. PMID: 39702630. doi:10.1007/s00330-024-11260-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。